Cargando…
Safety and Pharmacokinetics of CD101 IV, a Novel Echinocandin, in Healthy Adults
CD101 IV is a novel echinocandin with distinctive pharmacokinetic properties that is being developed as a once-weekly treatment for candidemia and invasive candidiasis. CD101 has potent in vitro activity and in vivo efficacy against a broad range of Candida and Aspergillus species. The primary objec...
Autores principales: | Sandison, Taylor, Ong, Voon, Lee, Jonathan, Thye, Dirk |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5278714/ https://www.ncbi.nlm.nih.gov/pubmed/27919901 http://dx.doi.org/10.1128/AAC.01627-16 |
Ejemplares similares
-
Pharmacokinetics of the Novel Echinocandin CD101 in Multiple Animal Species
por: Ong, Voon, et al.
Publicado: (2017) -
Preclinical Evaluation of the Stability, Safety, and Efficacy of CD101, a Novel Echinocandin
por: Ong, Voon, et al.
Publicado: (2016) -
Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata
por: Bader, Justin C., et al.
Publicado: (2018) -
Population Pharmacokinetic Analyses for Rezafungin (CD101) Efficacy Using Phase 1 Data
por: Lakota, Elizabeth A., et al.
Publicado: (2018) -
Structure-Activity Relationships of a Series of Echinocandins and the Discovery of CD101, a Highly Stable and Soluble Echinocandin with Distinctive Pharmacokinetic Properties
por: James, Kenneth D., et al.
Publicado: (2017)